FDA approval in GBM Agile will offer a huge spike no doubt - but that’s not the end game it’s just one station further down the line.
so if your time horizon is multiple conditions approved with more on the way and maybe 5+ years then there’s no need to sweat this year or even the next…
it’s clear data has been delayed from late last year - that’s a very very very good thing for patients and for us.
FDA approval in GBM Agile will offer a huge spike no doubt - but...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)